WuXi Biologics and ZaiDing Pharmaceuticals reached a research service agreement on the innovative T cell receptor.

On January 14th, WuXi Biologics announced that they had signed a research service agreement with ZaiDing Medicine for an innovative T-cell engager (TCE). ZaiDing Medicine will receive global exclusive rights for the development and commercialization of the TCE in the treatment of solid tumors. The discovery of this TCE is based on WuXi Biologics' proprietary CD3 technology platform, combined with their ability in researching multi-specific antibodies and cutting-edge biological insights. Three TCE molecules developed based on this platform are currently in clinical development. According to the agreement, WuXi Biologics will receive an upfront payment, and be eligible for development, regulatory, and sales milestone payments, as well as sales royalties and payments from subsequent licensing or other business development transactions.